No Data
Beijing Aosaikang Pharmaceutical (002755.SZ): The application for marketing authorization of the subsidiary Malibavir tablets has been accepted.
On January 3rd, Gelonghui reported that Beijing Aosaikang Pharmaceutical (002755.SZ) announced that its wholly-owned subsidiary Jiangsu Aosaikang Pharmaceutical Co., Ltd. (referred to as "subsidiary") recently received the acceptance notice for the listing application of Maribavir tablets issued by the National Medical Products Administration. Maribavir is an antiviral drug against human CMV, used for the treatment of cytomegalovirus (CMV) infections and/or diseases following hematopoietic stem cell transplantation or solid organ transplantation, and is intended for adult patients who are refractory to one or more previous treatments (such as Ganciclovir, Valganciclovir, Sidofovir, or Foscarnet) with or without genotype resistance.
Osecon: Report for the third quarter of 2024
beijing aosaikang pharmaceutical (002755.SZ) net income in the third quarter increased by 296.25% year-on-year.
Galunhui October 30th | Beijing Aosaikang Pharmaceutical (002755.SZ) released its third quarter report, with the company achieving revenue of 1.384 billion yuan in the first three quarters, a year-on-year increase of 23.64%; net income of 0.127 billion yuan, a year-on-year increase of 168.79%. In the third quarter alone, revenue reached 0.462 billion yuan, up 13.23% year-on-year; net income was 51.4232 million yuan, up 296.25% year-on-year.
Hong Kong stocks anomaly | Innovent Bio (01801) fell another 10% during the day, reaching a strategic cooperation with Beijing Aosaikang Pharmaceutical, the founder recently reduced holdings by over 0.15 billion Hong Kong dollars of stocks
Innovent Bio (01801) fell by another 10% during the day, as of the time of publication, a decrease of 4.92%, closing at HKD 47.35, with a turnover of 1.627 billion Hong Kong dollars.
Innovent Bio and Beijing Aosaikang Pharmaceutical have reached a global strategy cooperation for the third generation EGFR TKI lung cancer targeted drug Elunate tablets (Aoyixin).
San Francisco, usa and Suzhou, china - October 8, 2024 / PRNewswire / - On September 30, 2024, Innovent Bio (Hong Kong Stock Exchange stock code: 01801), a biopharmaceutical company dedicated to researching, developing, producing and selling innovative drugs in major disease areas such as oncology, autoimmune, cardiovascular and metabolism, ophthalmology, etc., announced a cooperation agreement with Beijing Aosaikang Pharmaceutical (Shenzhen Stock Exchange stock code: 002755), to declare that the two parties have reached an exclusive business agreement on the third-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) targeted drug Iletisib tablets (Oselex).
Osecon: 2024 Semi-Annual Report
No Data
